We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

on page 1 showing 20 out of 2,302 results from 1 sources

Cite this (1000 Genomes: A Deep Catalog of Human Genetic Variation, RRID:SCR_006828)

URL: http://www.1000genomes.org/

Resource Type: Resource, organization portal, database, consortium, data set, portal, data or information resource

International collaboration producing an extensive public catalog of human genetic variation, including SNPs and structural variants, and their haplotype contexts, in an effort to provide a foundation for investigating the relationship between genotype and phenotype. The genomes of about 2500 unidentified people from about 25 populations around the world were sequenced using next-generation sequencing technologies. Redundant sequencing on various platforms and by different groups of scientists of the same samples can be compared. The results of the study are freely and publicly accessible to researchers worldwide. The consortium identified the following populations whose DNA will be sequenced: Yoruba in Ibadan, Nigeria; Japanese in Tokyo; Chinese in Beijing; Utah residents with ancestry from northern and western Europe; Luhya in Webuye, Kenya; Maasai in Kinyawa, Kenya; Toscani in Italy; Gujarati Indians in Houston; Chinese in metropolitan Denver; people of Mexican ancestry in Los Angeles; and people of African ancestry in the southwestern United States. The goal Project is to find most genetic variants that have frequencies of at least 1% in the populations studied. Sequencing is still too expensive to deeply sequence the many samples being studied for this project. However, any particular region of the genome generally contains a limited number of haplotypes. Data can be combined across many samples to allow efficient detection of most of the variants in a region. The Project currently plans to sequence each sample to about 4X coverage; at this depth sequencing cannot provide the complete genotype of each sample, but should allow the detection of most variants with frequencies as low as 1%. Combining the data from 2500 samples should allow highly accurate estimation (imputation) of the variants and genotypes for each sample that were not seen directly by the light sequencing. All samples from the 1000 genomes are available as lymphoblastoid cell lines (LCLs) and LCL derived DNA from the Coriell Cell Repository as part of the NHGRI Catalog. The sequence and alignment data generated by the 1000genomes project is made available as quickly as possible via their mirrored ftp sites. ftp://ftp.1000genomes.ebi.ac.uk ftp://ftp-trace.ncbi.nlm.nih.gov/1000genomes

  • From Current Category


Cite this (3DVC, RRID:SCR_001377)

URL: http://www.3dvcell.org/conference-toward-3d-virtual-cell

Resource Type: Resource, portal, community building portal, data or information resource

Community of researchers attempting to build a comprehensive virtual cell model. The 3DVC will do for cell biology what the Large Hadron Collider (LHC) does for particle physics, but through a virtual rather than physical resource. It will bring together collaborators around a shared infrastructure to advance the field through efficient groundbreaking science and technology, the results of which will be broadly disseminated to an audience ranging from K12 to professionals. The 3DVC is committed to open science, yet strives for sustainability through new business models that leverages that open content.

  • From Current Category


Cite this (AAAS, RRID:SCR_013659)

URL: http://www.aaas.org/

Resource Type: Resource, organization portal, portal, data or information resource

It is an international non-profit organization dedicated to advancing science around the world by serving as an educator, leader, spokesperson and professional association. In addition to organizing membership activities, AAAS publishes the journal Science, as well as many scientific newsletters, books and reports, and spearheads programs that raise the bar of understanding for science worldwide. :AAAS History: Founded in 1848, AAAS serves some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of one million. The non-profit AAAS is open to all and fulfills its mission to advance science and serve society through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert!, the premier science-news Web site, a service of AAAS. :Membership and Programs: Open to all, AAAS membership includes a subscription to Science. Four primary program areas fulfill the AAAS mission: * Science and Policy * International Activities * Education and Human Resources * Project 2061 :AAAS Mission: AAAS seeks to advance science, engineering, and innovation throughout the world for the benefit of all people. To fulfill this mission, the AAAS Board has set these broad goals: * Enhance communication among scientists, engineers, and the public; * Promote and defend the integrity of science and its use; * Strengthen support for the science and technology enterprise; * Provide a voice for science on societal issues; * Promote the responsible use of science in public policy; * Strengthen and diversify the science and technology workforce; * Foster education in science and technology for everyone; * Increase public engagement with science and technology; and * Advance international cooperation in science. :

  • From Current Category


Cite this (AACC, RRID:SCR_011999)

URL: http://www.aacc.org/Pages/default.aspx

Resource Type: Resource, portal, community building portal, data or information resource

An international society comprised of medical professionals with an interest in clinical chemistry, clinical laboratory science, and laboratory medicine.

  • From Current Category

Cite this ( AASK Clinical Trial and Cohort Study , RRID:SCR_006985)

URL: http://archives.niddk.nih.gov/patient/aask/aask.aspx

Resource Type: Resource, disease-related portal, topical portal, resource, research forum portal, portal, clinical trial, data or information resource

Clinical trial investigating whether a specific class of antihypertensive drugs (beta-adrenergic blockers, calcium channel blockers, or angiotensin converting enzyme inhibitors) and/or the level of blood pressure would influence progression of hypertensive kidney disease in African Americans. The initiative consisting of 21 clinical centers and a data-coordinating center is followed by a Continuation of AASK Cohort Study to investigate the environmental, socio-economic, genetic, physiologic, and other co-morbid factors that influence progression of kidney disease in a well-characterized cohort of African Americans with hypertensive kidney disease. Only patients who were previously in the randomized trial are eligible for the cohort study. A significant discovery was made in the treatment strategy for slowing kidney disease caused by hypertension. Angiotensin-converting enzyme (ACE) inhibitors, compared with calcium channel blockers, were found to slow kidney disease progression by 36 percent, and they drastically reduced the risk of kidney failure by 48 percent in patients who had at least one gram of protein in the urine, a sign of kidney failure. ACE inhibitors have been the preferred treatment for hypertension caused by diabetes since 1994; however, calcium channel blockers have been particularly effective in controlling blood pressure in African Americans. The AASK study now recommends ACE inhibitors to protect the kidneys from the damaging effects of hypertension. The Continuation of AASK Cohort Study will be followed at the clinical centers. The patients will be provided with the usual clinical care given to all such patients at the respective centers. Baseline demographic information, selected laboratory tests, and other studies are being obtained at the initiation of the Continuation Study. The patients will be seen quarterly at the centers, and some selected studies done at these visits. Samples will be obtained and stored for additional studies and analyses at a later date.

  • From Current Category

Cite this (AASLD - American Association for the Study of Liver Diseases, RRID:SCR_012900)

URL: http://www.aasld.org/Pages/Default.aspx

Resource Type: Resource, topical portal, portal, data or information resource

A non-profit organization of scientists and healthcare professionals committed to preventing and curing liver disease, which runs three journals and an annual meeting. Its mission is to Advance the Science and Practice of Hepatology, Liver Transplantation and Hepatobiliary Surgery, Thereby Promoting Liver Health and Optimal Care of Patients with Liver and Biliary Tract Diseases. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology. AASLD has grown to an international society responsible for all aspects of hepatology, and our annual meeting, The Liver Meeting, has grown in attendance from 12 to over 7,000 physicians, surgeons, researchers, and allied health professionals from around the world. AASLD sponsors two to four Single Topic Conferences each year in clinical, basic, hepatitis, or pediatric hepatology. Our two monthly journals, HEPATOLOGY and Liver Transplantation, provide the latest research findings for hepatology and surgery of the liver. AASLD''s membership includes ALL professionals dedicated to hepatobiliary discoveries and patient care. Mentoring, the sharing of knowledge, and dedication to professional growth and development are among the core values of AASLD and its members.

  • From Current Category


Cite this (Abbott, RRID:SCR_010477)

URL: http://www.abbott.com/

Resource Type: Resource, portal, organization portal, commercial organization, data or information resource

An American pharmaceuticals and health care products company that since splitting into Abbott and AbbVie, focuses on diversified medical products. (AbbVie focuses on research-based pharmaceuticals) It has 90,000 employees and operates in over 130 countries. The company headquarters are in Abbott Park, North Chicago, Illinois. (adapted from Wikipedia)

  • From Current Category


Cite this (AbbVie, RRID:SCR_010484)

URL: http://www.abbvie.com/

Resource Type: Organization, portal, organization portal, commercial organization, data or information resource

A research-based biopharmaceutical company that develops advanced therapies to address global health problems.

  • From Current Category


Cite this (ABIRISK, RRID:SCR_003740)

URL: http://www.abirisk.eu/

Resource Type: Resource, organization portal, portal, consortium, data or information resource

A consortium that seeks to provide an integrated approach to anti-drug immunization by evaluating immunogenicity in hemophilia A, multiple sclerosis, and inflammatory diseases, and exploring new tools for protein drug immunogenicity. The data collected will be pooled in a single immunogenicity databank and will be standardized and used to develop models of anti-drug antibodies. By examining the correlation between patient and clinical factors and the incidence of immunogenicity, it hopes to reduce the regulatory and resource burdens of immunogenicity testing. The objectives of the consortium are: # Access to large cohorts of patients treated with marketed biopharmaceutical products # Complementary expertise for anti-drug antibodies (ADA) assays; standardization and characterization of ADA # Novel integrated approaches to characterize anti-drug lymphocyte responses # Development and validation of innovative prediction tools # Collection and integration of immunogenicity-related data and clinical relevance of ADA ABIRISK is grouped into five working projects, which communicate with one another and provide each other with results and data for analysis. The five working projects are: ADA assay development and validation and cohort management; cellular characterization and mechanisms of the AD immune response; evaluation and development of technologies for predicting immunogenicity; establishment of database, data analyses and integration; and project management and communication.

  • From Current Category

Cite this (Academia.edu, RRID:SCR_000080)

URL: http://www.academia.edu/

Resource Type: Resource, portal, community building portal, data or information resource

Social networking site for academic researchers that allows researchers to share papers, find people working in a field and see analytics on papers etc

  • From Current Category

Cite this (Academic Drug Discovery Consortium, RRID:SCR_003706)

URL: http://www.addconsortium.org/

Resource Type: Resource, organization portal, portal, consortium, data or information resource

A collaborative network among university-led drug discovery centers and programs to allow scientists to exchange technical expertise on drug discovery and development strategies as well as form partnerships with each other, biopharma companies, and drug discovery-focused contract service organizations and consultants. The website will also serve as a repository for drug discovery events, educational material, job postings, and partnership opportunities. Through active member participation this website will become a valuable tool for every scientist working in the drug discovery arena. In addition, involvement of members will enable them to effectively advocate to the NIH and other funding agencies to increase the awareness of the growing number of academic drug discovery scientists and their success as well as their needs.

  • From Current Category

Cite this (Academy of Finland, RRID:SCR_007394)

URL: http://www.aka.fi/en-gb/A/

Resource Type: Resource, organization portal, portal, funding resource, data or information resource

A funding agency for basic research in Finland and operates within the administrative sector of the Ministry of Education. Their mission is to finance high-quality scientific research, act as a science and science policy expert, and strengthen the position of science and research. The Academy works to contribute to the renewal, diversification and increasing internationalisation of Finnish research. Its operation covers the full spectrum of scientific disciplines.

  • From Current Category

Cite this (Accelerated Cure Project for Multiple Sclerosis, RRID:SCR_004743)

URL: http://www.acceleratedcure.org/index.php

Resource Type: Resource, disease-related portal, topical portal, portal, data or information resource

A national nonprofit organization dedicated to accelerating the cure of MS by facilitating research that determines the causes and mechanisms of MS. Our main effort is the creation of a large-scale, multidisciplinary MS Repository of blood samples and data from people with MS and matched controls. We make these samples available to researchers investigating the causes of MS and other demyelinating diseases. In exchange for access to the repository, researchers agree to return the data they generate from the samples so that results from disparate experiments can be combined. We are also developing a Cure Map to establish and document what is known and what is not known about the causes of MS. From the Cure Map, Accelerated Cure Project will facilitate the research most likely to reveal the causes of MS in the shortest time through use of our MS Repository.

  • From Current Category

Cite this (Accelerating Medicines Partnership - Alzheimers, RRID:SCR_003742)

URL: http://www.nih.gov/science/amp/alzheimers.htm

Resource Type: Resource, organization portal, portal, consortium, data or information resource

The Alzheimer's disease arm of the Accelerating Medicines Partnership (AMP) that will identify biomarkers that can predict clinical outcomes, conduct a large scale analysis of human AD patient brain tissue samples to validate biological targets, and to increase the understanding of molecular pathways involved in the disease to identify new potential therapeutic targets. The initiative will deposit all data in a repository that will be accessible for use by the biomedical community. The five year endeavor, beginning in 2014, will result in several sets of project outcomes. For the biomarkers project, tau imaging and EEG data will be released in year two, as baseline data becomes available. Completed data from the randomized, blinded trials will be added after the end of the five year studies. This will include both imaging data and data from blood and spinal fluid biomarker studies. For the network analysis project, each project will general several network models of late onset AD (LOAD) and identify key drivers of disease pathogensis by the end of year three. Years four and five will be dedicated to validating the novel targets and refining the network models of LOAD, including screening novel compounds or drugs already in use for other conditions that may have the ability to modulate the likely targets.

  • From Current Category

Cite this (Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus, RRID:SCR_003731)

URL: http://www.nih.gov/science/amp/autoimmune.htm

Resource Type: Resource, organization portal, portal, consortium, data or information resource

The autoimmune disease arm of the Accelerating Medicine Partnership (AMP), which aims to identify and validate the most promising biological targets of disease for new diagnostic and drug development, that is focused on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). They seek to identify shared common flaws in inflammation, particularly those that are shared with a larger number of autoimmune disorders which can cause severe disability, greatly affect quality of life, and are associated with an increased risk of death. This project aims to reveal biomarkers and biological targets for drug development, matching existing drugs to patients with specific molecular profiles who are most likely to benefit. The research plan proposes a 5 year process. Year one will include startup activities such as validation of tissue acquisition processes and analytic technologies, and the development of operating procedures. The second year will focus on identification of disease specific pathways by comparing data from patients and healthy individuals. Years 3-5 will expand the scale to include comparisons of different subsets of patients with RA or lupus to allow molecularly based patient stratification for precise treatment. The final 12 months (2019) will also include preliminary target validation. The data will be made publicly available through an internet-based information portal.

  • From Current Category

Cite this (Accelerating Medicines Partnership - Diabetes, RRID:SCR_003743)

URL: http://www.nih.gov/science/amp/type2diabetes.htm

Resource Type: Resource, organization portal, portal, consortium, data or information resource

The arm of the Accelerating Medicine Partnership (AMP) that is focused on identifying genetic biomarkers that are correlated to Type 2 diabetes, with particularly emphasis on accelerating development of novel drugs for this disease. While therapies are available for Type 2 Diabetes (T2D), none can reverse disease progression or prevent complications of the disease. The approach of this project is to use and supplement a large amount of recently generated genetic data on T2D in diverse populations. The goal is to validate novel molecules and pathways as targets for therapeutic development. The AMP initiative will deposit all data in a repository that will be accessible for use by the biomedical community. Over the five years, researchers will build a database of DNA sequence, functional genomic and epigenomic information, and clinical data from studies on type 2 diabetes and its cardiac and renal complications. This will involve data from 100,000-150,000 individuals combined into a T2D knowledge portal accessible to academic and industry researchers to identify and validate changes in DNA that spur the onset of diabetes, alter disease severity, speed or slow down disease progression, or have a protective effect. In addition, new genomic that fills in gaps in the knowledge portal will be generated by executing specific analysis, including DNA sequencing of particular individuals.

  • From Current Category

Cite this (Accurate Recognition of Transcription Starts in Human, RRID:SCR_008386)

URL: http://www.fml.tuebingen.mpg.de/raetsch/projects/arts

Resource Type: Resource, topical portal, portal, data or information resource

ARTS are new methods for finding transcription start sites (TSS) of RNA Polymerase II binding genes in genomic DNA sequences. Employing Support Vector Machines with advanced sequence kernels, we achieve drastically higher prediction accuracies than state-of-the-art methods. While ARTS'' predictions are point-wise, resolution has been decreased to 1/50 and 1/500 respectively to reduce traffic. Also note that these scores are real-valued, i.e. no artificial cut-off value has been set. This has the advantage that one may choose the cut-off threshold based on ones own cost function and that the relative promoter activity is visible. Finally, note that non ACGT bases have been randomly substituted, therefore especially long N-sleds may completely screw up results on not yet reliably annotated chromosome parts. Sponsors: This resource is partially supported by the PASCAL Network of Excellence (EU #506778), DFG grants JA 379/13-2 and MU 987/2-1. :Keywords: Transcription, Human, RNA polymerase II, binding, Gene, Genomic, DNA, Sequence, :

  • From Current Category

Cite this (Action to Control Cardiovascular Disease Risk in Diabetes Follow-up Study (ACCORDION), RRID:SCR_014373)

URL: https://www.accordionstudy.org/public/dspHome.cfm

Resource Type: Resource, data set, topical portal, portal, data or information resource

A prospective, observational follow-up study of at least 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Treatment in ACCORD ended in 2009 and ACCORDION is designed to further elucidate the long-term effects of the ACCORD treatment strategies and provide additional data on the relationships among various cardiovascular and diabetic risk factors.

  • From Current Category

Cite this (ACTREC - Advanced Centre for Treatment Research and Education in Cancer, RRID:SCR_006021)

URL: http://www.actrec.gov.in/

Resource Type: Resource, topical portal, portal, data or information resource

The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India. ACTREC comprises of 2 arms - one for basic research and another for clinical research. The basic research building was inaugurated in March 2002 at the new site of ACTREC in Kharghar, Navi Mumbai. In August 2002, the Cancer Research Institute (CRI) shifted in toto from its Parel campus in Mumbai to serve as the basic research arm of ACTREC. The clinical research arm of ACTREC comprising of the Clinical Research Centre (CRC) has become functional from March 2005. ACTREC also has a 50-bed hospital fully equipped with state-of-the-art diagnostic and therapeutic facilities. Research investigations at CRI currently focus on molecular mechanisms responsible for causation of major human cancers relevant to India. It is envisaged that in the future, ACTREC will play a greater role in drug development and emerging therapies for treatment and prevention of cancer.

  • From Current Category


Cite this (ACTTION, RRID:SCR_004003)

URL: http://www.acttion.org/

Resource Type: Resource, organization portal, portal, consortium, data or information resource

A public-private partnership with the United States Food and Drug Administration (FDA) to identify, prioritize, sponsor, coordinate, and promote innovative activities - with a special interest in optimizing clinical trials - that will expedite the discovery and development of improved analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety. This multi-year, multi-phase initiative is closely aligned with the FDA''''s Critical Path Initiative. The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders - including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations - with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency. ACTTION launched an initiative to develop training materials for clinical trial subjects (and staff) to be used with pain rating scales and other pain-related patient reported outcomes. Once materials have been developed and evaluated, proof-of-concept trials will be conducted to test the hypothesis that patient and staff training can improve the assay sensitivity of analgesic trials.

  • From Current Category

  1. Resource Identification Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Save Your Search

    You can save any searches you perform for quick access to later from here.

  6. Query Expansion

    We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.

  7. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  8. Sources

    Here are the sources that were queried against in your search that you can investigate further.

  9. Categories

    Here are the categories present within RRID that you can filter your data on

  10. Subcategories

    Here are the subcategories present within this category that you can filter your data on

  11. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.